ArticleHormones (Athens, Greece)2026
Effectiveness of vitamin E in the treatment of diabetic neuropathy: systematic review and meta-analysis.
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate whether tocotrienol-rich vitamin E improves nerve-conduction parameters and symptoms in diabetic peripheral neuropathy (DPN).
methodsFollowing Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA 2020 (PROSPERO CRD420250653145), we searched the PubMed, Web of Science, Scopus, and Embase databases up until 20 March 2025, for parallel-group randomized controlled trials (RCTs) of oral vitamin E in adults (≥ 18 years) with electrophysiologically confirmed DPN. Two independent reviewers performed screening, extraction, and the revised Cochrane Risk of Bias tool version 2.0 (RoB 2.0). Random-effects meta-analyses were conducted using the mean differences (MD) with 95% confidence intervals (CI).
resultsFive RCTs (n = 660) met the criteria. Tocotrienol-rich vitamin E increased sural sensory nerve-conduction velocity (NCV) by 1.77 m s⁻¹ (0.80-2.74) and median sensory NCV by 1.53 m s⁻¹ (0.44-2.63); tibial motor NCV rose 1.47 m s⁻¹ (0.36-2.58) versus placebo. Nerve-action-potential amplitudes and glycated hemoglobin A1c (HbA₁c) were unchanged (MD - 0.06%, - 0.18-0.06). Adverse-event rates were similar between groups. Two trials had a low risk of bias; one presented some concerns. DISCUSSION: Vitamin E yielded selective NCV gains without amplitude change, suggesting preservation or remyelination of sensory fibers rather than axonal regeneration. The absence of glycemic effects indicates neuroprotection independent of glucose control, positioning vitamin E as a potential adjunct-not substitute-to antidiabetic therapy. Heterogeneity in isoform, dose, and treatment duration (≤ 12 months) and modest sample sizes limit certainty. Larger, longer trials incorporating functional outcomes (pain, gait, and quality of life) are required.
Indexed as
Identifiers
41528693What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.